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Abstract
Objectives: Endothelial dysfunction precedes atherogenesis and clinical complications in type 2 diabetes. The 
vascular dysfunction in Zucker diabetic fatty (ZDF) rats was evaluated at different ages along with the effect of 
treatment with rosiglitazone (Rosi) on endothelial function and mechanical remodeling.
Methods: The Rosi treatment was given to ZDF rats for 3 weeks. The endothelium-dependent vasodilation and α-
adrenoceptor-dependent vasoconstriction of femoral arteries were studied using an ex-vivo isovolumic myograph. The 
biomechanical passive property of the arteries was studied in Ca2+-free condition. The expressions of endothelial nitric 
oxide synthase (eNOS), α-adrenoceptor, matrix metalloproteinase 9 (MMP9), and elastase were evaluated.
Results: Endothelium-dependent vasorelaxation of the femoral artery was blunted at low doses in ZDF rats at 11 
weeks of age and attenuated at all doses in ZDF rats at 19 weeks of age. The expression of eNOS was consistent with 
the endothelium-dependent vasorelaxation. The α-adrenoceptor was activated and the mechanical elastic modulus 
was increased in ZDF rats at 19 weeks of age. The expressions of α-adrenoceptor, MMP9, and elastase were up 
regulated in ZDF rats at 19 weeks of age. Rosi treatment for 3 weeks restored endothelium-dependent vasorelaxation 
and the expression of eNOS and the adrenoceptor activation at the doses below 10-6 mole/L in ZDF rats at 19 weeks of 
age. Rosi treatment for 3 weeks did not, however, improve the mechanical properties of blood vessel, the expressions 
of α-adrenoceptor, MMP9, and elastase in ZDF rats.
Conclusion: The endothelial dysfunction and mechanical remodeling are observed as early as 19 weeks of age in ZDF 
rat. Rosi treatment for 3 weeks improves endothelial function but not mechanical properties.
Introduction
Cardiovascular disease (CVD) is the major cause of mor-
tality and morbidity in people with type 2 diabetes melli-
tus (T2DM) and macrovascular disease is the leading
cause of mortality in T2DM [1-7]. Endothelial dysfunc-
tion is a significant biomarker of early stage of CVD,
which can be detected functionally as changes in vasomo-
tor responses, cell proliferation, platelet adhesion/aggre-
gation, vascular permeability, or leucocyte/endothelial
interaction [6,8-10]. T2DM and its companion complica-
tions (atheroscleropathy) are associated with multiple
metabolic toxicities and chronic injurious stimuli that
result in vascular remodeling, including fibrosis, struc-
tural derangement, tissue or organ dysfunction, and ulti-
mate failure as a result of loss of form (structure) and
function [1,4,11]. Endothelial dysfunction is considered
as one of the instigators of atherosclerosis during the
development of T2DM and the major cause of vascular
remodeling triggered by increase of growth factor release
ranging from platelets to leucocytes which trigger the
pathway of reactive oxygen species (ROS), and imbalance
of matrix metalloproteinase (MMPs) and the collagens
within vascular extracellular matrix (ECM) [1,10,11]. The
changes in biomechanical properties have been docu-
mented in diabetes which reflect the micro-structural
remodeling (elastin and collagen) of the vessel wall [12-
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improved with drug treatment through renin-angiotensin
system blockers, β-blockers, Calcium antagonists, and
others [7]. The drugs for lipid management have been
shown to reduce macrovascular disease and improve
endothelial function [3]. Both endothelial and vascular
smooth muscle cells are involved in the remodeling of
vessel wall in diabetes [11,16,18].
It is widely reported that vascular function is compro-
mised in ZDF rat which is a well-established T2DM ani-
mal model [5,19,20]. Thiazolidinediones (TZD) act as
agonists of the peroxisome proliferation-activated recep-
tor γ (PPARγ), improve insulin resistance, and reduce free
fatty acid (FFA) in patients with T2DM [20,21]. The TZD
rosiglitazone (Rosi) enhances endothelial function and
increases nitric oxide (NO) release in patients with
T2DM [21,22]. Rosi has also been reported to improve
endothelium-dependent vascular dysfunction in ZDF rats
[5].
It is unclear if the remodeling of mechanical property of
the vessel wall is reversed in T2DM animal model along
with improvement of endothelial function with Rosi
treatment in short term. In present study, we measured
the endothelial function with a novel myograph and bio-
mechanical properties (stress-strain relationship) of fem-
oral artery in ZDF rats with/without Rosi treatment and
their age-match groups. The biomarkers, including vas-
cular reactivation and expression of eNOS (for endothe-
lial functions), α-adrenoceptor (for vascular remodeling
and smooth muscle hypertrophy), MMP9 (for remodel-
ing of basement membrane of blood vessel), and elastase
(for remodeling of extracellular matrices, especially elas-
tin), were also evaluated in this study.
Materials and methods
The animal experiments were performed in accordance
with the guidelines of Institute of Laboratory Animal
Research Guide, Public Health Service Policy, Animal
welfare Act, and an approved PreClinOmics IACUC pro-
tocol.
Animals and treatments
Zucker diabetic fatty (ZDF) and Zucker lean littermate
rats were obtained from Charles River. ZDF and lean rats
were fed with a commercial rodent chow Purina 5008 ad
libitum. The body weight was measured weekly. The
baseline glucose and triglycerides were measured in
whole blood taken from the tail vein in the morning of
the terminal study. The animals were randomly divided
into age-matched and compound-treated groups. Age-
matched groups had two subgroups: 11-weeks and 19-
weeks. There were vehicle and rosiglitazone (Rosi)
treated groups from 16 weeks to 19 weeks of age. The
vehicle treated group was orally gavaged with 1% CMC/
0.25% Ten 80 at 10 ml/kg. The compound Rosi treated
group was given 3 mg/kg/day Rosi in vehicle in the morn-
ing by oral gavage as outlined in previous reports [5,20].
Tissue preparation and isovolumic myograph
On the day of termination, the rat was weighed and blood
was sampled. The animal was anesthetized with isoflu-
rane. The left superficial femoral artery (SFA) was cannu-
lated to measure physiologic pressure, which indicates
the blood pressure in a small artery (outer diameter of
SFA is about 0.4 mm). The right common femoral artery
was excised quickly and placed in cold physiological
saline solution (PSS in mmole/L: 119 NaCl, 4.7 KCl, 25
NaHCO3, 1.17 KH2PO4, 1.17 MgSO4, 1.6 CaCl, 5.5 Dex-
trose, solution gassed by 95% O2 5% CO2). The animal
was euthanized by overanesthesia with isoflurane. The
left common femoral artery was excised and stored at -
30°C for detection of protein expression. The branches on
the right common femoral artery were ligated and the
vessel was cannulated with connectors. The vessel was
warmed up to 37°C slowly (20 - 25 min) and equilibrated
for 40 minutes at a transmural pressure of 15 mmHg and
in situ length.
The isovolumic system consisted of a chamber with two
connectors which bridge the blood vessel and thick-wall
tubes [23]. A volume compensator injected PSS into the
vessel to offset the permeability of the vessel wall to
maintain constant volume (i.e., isovolumic myograph).
The aerated (95% O2 5% CO2) PSS filled the chamber
tubes before vessel cannulation. The vessel was inflated
to a desired pressure, e.g., physiologic pressure. To
achieve an isovolumic condition, a clamp placed on the
tube between the pressurized flask and the connector was
closed and the PSS in the lumen of the vessel and tubes
was sealed. The vascular contraction or relaxation in
response to chemical stimulation was characterized by
change of intraluminal pressure while the vessel diameter
was tracked simultaneously.
Vascular functions in response to agonist/antagonist
The dose-response vasoconstriction to phenylephrine
(PE, an agonist of α-adrenoceptor) was performed to
evaluate the activation of α-adrenoceptor (10-11 to 10-4
mole/L). To evaluate endothelium-dependent dose-
response relaxation to acetylcholine (ACh, 10-12 to 10-5
mole/L) or endothelium-independent dose-response
relaxation to sodium nitroprusside (SNP, 10-9 to 10-5
mole/L), the vessel was pre-constricted with sub-maxi-
mal dose of PE. KCl (60 mM) was added to the bath to
test vessel viability. Since diabetes and hypertension are
common co-morbidities, we investigated the synergistic
effect of acute over-inflation in the diabetic vessels on
endothelial function. The artery was stretched to physio-
logic axial stretch ratio of 1.3 and inflated to a hyperten-
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endothelium-dependent (ACh) and -independent (SNP)
relaxations were performed according to the above proto-
col.
The circumferential contractile tensions were com-
puted at every PE concentration using Eq. [1]. The per-
cent relaxation was indicated with the ratio of change in
tension at every ACh concentration or SNP concentra-
tion to the decrease in tension relative to maximal con-
centration. The circumferential tension was computed
based on Laplace's equation:
where T is circumferential tension and P is transmural
pressure. rint is internal radius of blood vessel related to
the external radius and given by the incompressibility
assumption.
where A0 is the cross-sectional wall area of vessel at no-
load state (zero transmural pressure) and λ is axial stretch
ratio.
Passive mechanical properties
After fully relaxed in Ca2+ free enviroment, the vessel seg-
ment was inflated from 0 to 160 mmHg at rate of ~4
mmHg per second and then deflated to zero. The passive
pressure-diameter was recorded after 3 cycles of precon-
ditioning. The circumferential Kirchhoff stress was com-
puted with the following equation:
where p is the pressure. rint is the inner radius com-
puted from Eq [1B]. h is wall thickness of the vessel seg-
ment (h = rext - rint). λ is the circumferential stretch ratio
and the midwall Green strain was computed as follow:
The elastic modulus, E, in the physiological state was
calculated as:
where εphysio is the circumferential strain at physiologi-
cal state.
Expressions of eNOS, α-adrenoceptor, MMP9, and elastase
Briefly, the protein extracts (~25 μg) from arterial tissues
were fractionated on 10% SDS-PAGE gel, transferred
onto polyvinylidene difluoride membrane, and probed
with the following primary antibodies: anti-eNOS (BD
transduction laboratory), anti-α-adrenoceptor (ABCam),
anti-MMP9 and anti-elastase (Santa Cruz Biotech). Blots
were incubated with horseradish peroxidase-conjugated
secondary antibody. The signal was detected by enhanced
chemiluminescence (ECL, Amersham) and evaluated by
densitometry (Sigma Scan). β-actin was used for normal-
ization.
Statistics
The data were presented as mean ± SD. Significant differ-
ences between two data points were determined by stu-
dent t-test. Significant differences between the dose-
dependent groups and stress-strain relationship were
determined by use of Analysis Of Variance (ANOVA)
between groups. A probability of p < 0.05 was considered
to be indicative of a statistically significant difference.
Results
The ages and numbers of animals in the various groups
are represented in Table 1. The average blood pressure in
superficial femoral artery (Table 1) were not significantly
different in various groups (P > 0.05), This result indi-
cates that the blood pressure in a smaller artery is similar
to central arterial pressure which does not significantly
increase in ZDF rats as previously reported [5]. The body
weight increased in lean rats from 11 to 19 weeks of age
but not in ZDF rats (Table 1). Although the vehicle treat-
ment did not change the body weight, Rosi treatment
increased the body weight of ZDF rats similar to previous
reports [5,21]. Plasma glucose (Table 1) was significantly
increased in ZDF rats (p < 0.05) in both 11 and 19 weeks
of age but not in lean rats (p > 0.1). Plasma glucose in the
Rosi treated ZDF rats did not decrease significantly (p >
0.05) and remained at high concentration. The concen-
trations of plasma triglycerides were significantly
increased in ZDF rats but not statistically changed (p >
0.05) after Rosi treatment (Table 1).
Figure 1A shows endothelial dysfunction as early as 19
weeks of age in ZDF rats (p < 0.05). Even at 11 weeks of
age, the endothelium-dependent relaxation of ZDF rats
was blunted at concentrations lower than 10-9 mole/L
(Figure 1A) in comparison with lean rats (p < 0.05). After
treatment with Rosi, endothelial function recovered to
the level of lean animal (p > 0.05) despite a significantly
elevated concentration of plasma glucose (Figure 1B).
Endothelium-independent relaxation to SNP failed to
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Page 4 of 8reveal differences before and after Rosi treatment (data
not shown) and served as control.
In Figure 2, we observed the effect of acute over-infla-
tion (170% of physiologic pressure) in the ZDF and lean
vessels on endothelial functions. The acute over-stretch
significantly augmented endothelium-dependent dys-
function of artery in ZDF rats as compared to lean rats (p
< 0.05). In the condition of acute over-stretch, the Rosi
treatment essentially restored the endothelium-depen-
dent relaxation of artery in ZDF rats to the level of artery
in lean rats.
The circumferential tension increased (p < 0.05) during
PE stimulation in ZDF rats at 19 weeks of age (Figure 3A)
but not at 11 weeks of age (p > 0.05). The circumferential
tensions in response to 60 mM KCl were not statistically
different among various ages of lean and ZDF animals
(5.1 ± 1.2 kPa in lean animals at 19 weeks of age, 5.2 ± 0.9
kPa at 11 weeks of age, and 5.0 ± 1.3 kPa at 19 weeks of
age). This observation implies that the adrenergic vaso-
constriction is augmented in ZDF rats and similar to the
observation in Zucker obese rat [24]. Rosi treatment
restored the adrenergic vasoconstriction in the range of
low concentration of PE (<10-6 mole/L). At high concen-
trations of PE (1 × 10-5 mole/L), the vasoconstriction was
the same as without treatment (Figure 3B).
The passive pressure-diameter and stress-strain rela-
tionship were presented in Figure 4 and 5. There were no
significant changes of pressure-diameter and stress-strain
relationship between 11 weeks and 19 weeks of age in
lean rats. The vessel of ZDF rats at 11 weeks of age was
not statistically stiffer in comparison with age-matched
lean rats (11 weeks of age) (Figure 5A). However, the ves-
sel of ZDF rats at 19 weeks became significantly stiffer (p
< 0.05) in comparison with lean rats at 19 weeks of age
(Figure 5B). The treatment of Rosi did not restore the
stress-strain relationship and the elastic modulus did not
change in comparison with untreated group (Figure 5C).
The expression of eNOS significantly down regulated
in ZDF rats at 19 weeks of age but not at 11 weeks of age
(Figure 6A). The expression of α-adrenoceptor up regu-
lated in ZDF rats at 19 weeks of age but not at 11 weeks of
age (Figure 6B). The increase in vasoconstriction in
response to PE implies enhanced activity of α-adrenocep-
tor in ZDF rats at 19 weeks of age. The up regulation of
MMP9 indicates remodeling of vessel wall (Figure 6C)
and may correlate with endothelium function since the
target of MMP9 is the basement membrane of blood ves-
sel. We also observed up regulation of elastase in ZDF
rats at 19 weeks of age (Figure 6D), where elastase is a
well-known biomarker of vascular remodeling. The Rosi
treatment did not reverse the up regulation of the expres-
sions of either α-adrenoceptor, MMP9, or elastase in the
vessel wall (Figure 6). The treatment of Rosi reversed the
expression of eNOS, however, which is consistent with
the observation on the endothelium-dependent vasore-
laxation in this study.
Discussion
In present study, the endothelium-dependent vasorelax-
ation in response to ACh was attenuated and the expres-
sion of eNOS down regulated in ZDF rats at 19 weeks of
age in comparison to Zucker lean rats. The acute over-
inflation (simulates acute hypertension) compromised
the endothelium-dependent relaxation of artery in both
ZDF and lean rats but more so in the ZDF rats. The pas-
sive stress-strain relationships reflect the biomechanical
properties of blood vessel and a leftward shift suggests an
increased elastic modulus at 19 weeks of age in ZDF rats.
This is consistent with our previous observation of stiffer
arteries in streptozotocin-induced diabetes [17]. The
treatment for 3 weeks of Rosi improved endothelial func-
tion but did not alter the passive mechanical properties.
The up regulations of α-adrenoceptor, MMP9, and
Table 1: Effect of age and the treatment of Rosiglitazone on body weight, average arterial pressure, blood glucose, and 
triglycerides.
11 weeks 19 weeks 19 weeks
Determination Lean ZDF Lean ZDF Veihcle Rosi
Number of Animals 6 7 6 6 6 6
Age of Animal (weeks) 11.8 ± 1.2 11.3 ± 0.9 19.7 ± 1.5 19.2 ± 1.1 19.6 ± 1.5 19.3 ± 1.2
Average Pressure (mmHg) 69.2 ± 8.9 71.7 ± 9.3 72.2 ± 9.7 74.8 ± 11.6 71.9 ± 10.3 73.9 ± 11.8
Body Weight (grams) 339 ± 38 369 ± 35 382 ± 35 401 ± 37* 403 ± 29* 423 ± 33*
Glucose (mg/dl) 112.8 ± 16.1 457.8 ± 35.9* 116.3 ± 15.0 431.4 ± 30.3* 472.0 ± 46.0* 445.6 ± 48.8*
Triglyceride (mg/dl) 108.3 ± 11.9 583.4 ± 49.5* 121.8 ± 16.5 602.6 ± 59.7* 609.1 ± 79.7* 613.1 ± 46.5*
Notes: Lean: Zucker lean rats. ZDF: Zucker diabetic fatty rats. Rosi: rosiglitazone treated. * p < 0.05 compared with lean rats.
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in ZDF rats with/without Rosi treatment.
ZDF rats are inbred from a colony of obese Zucker rats
with a hyperglycemic phenotype. The blood glucose in all
fatty males of ZDF rat model increases more than 4-fold
by 10 weeks of age when fed Purina 5008 and remains at
this high level throughout their lifespan. Although
between 10-13 weeks of age, the serum insulin is ele-
vated, it declines progressively with advancing age.
Between 22-42 weeks of age, serum insulin levels decline
to below the levels of insulin in age-matched lean control
rats due to pancreatic beta cell failure and renal injury
develops [19]. In the present study, the ages of the ani-
mals were selected at 11 weeks of age at the initiation of
hyperglycemia and at 19 weeks of age when diabetic com-
plications had not significantly occurred. Endothelial dys-
function has been reported in ZDF rats at 16-24 weeks in
coronary artery and over 22 weeks in aorta [5,8].
Here, we report endothelial dysfunction in significantly
younger rats in the common femoral artery. Endothelial
dysfunction of common femoral artery was detected in
ZDF rats as early as 11 weeks in response to low concen-
tration of ACh which may be attributed to the more phys-
iologic loading in both inflation and axial elongation.
Hypertension is very frequent among T2DM [2]. The
occurrence of diabetes and hypertension are multiplica-
tive risk factors for macro- and micro- vascular diseases
and endothelial dysfunction is considered as one of the
biomarkers of atherosclerosis during the development of
T2DM [6]. Our results show that acute hypertension
causes profound endothelial dysfunction in ZDF rat.
Hence, distension of a ZDF vessel causes a confounding
deleterious effect on endothelial function.
The vasoconstriction in response to PE may reflect the
activation of the α-adrenoeceptor. The up regulation of α-
adrenoceptor's activation and expression implies vascular
hypertrophy and remodeling [25-27]. T2DM often lead to
matrix deposition and glycation in blood vessel wall, par-
ticularly those proteins associated with the basement
membrane, and increase in stiffness or decrease in dis-
tensibility of blood vessel [11]. The up regulation of
MMP9 indicates matrix remodeling and especially the
remodeling of basement membrane. The increased
expression of elastase reflects degradation of elastin
fibers and hence increased stiffness of the vessel wall.
Rosi treatment restored the compromised endothe-
lium-dependent vasorelaxation in ZDF rats at the 19
Figure 1 The endothelium-dependent dose-response vasorelax-
ation for the various groups. A: Effect of age (11 wks and 19 wks) on 
the vasorelaxation of ZDF rats in comparison with lean rats. B: Effects 
of Rosi on the vasorelaxation of ZDF rats in comparison with lean rats. 
Lean: Zucker lean rats. ZDF: ZDF rats. Rosi: rosiglitazone treatment. 
11w: 11 weeks of age. 19w: 19 weeks of age. #: ANOVA analysis indi-
cates statistical difference (p < 0.05) of the dose-dependent curve be-
tween the ZDF rats at different age and lean rats. *: Significant 
difference (p < 0.05) at single dose between ZDF rats at different age 
and lean rats.
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Figure 2 The deleteriousness effect of acute over-inflation on the 
endothelium-dependent (ACh) and endothelium-independent 
(SNP) vasorelaxation. Lean: Zucker lean rats. ZDF: ZDF rats. Rosi: 
rosiglitazone treatment. 19w: 19 weeks of age. #: ANOVA analysis indi-
cates statistical difference (p < 0.05) of the dose-response curves of 
ZDF rats between SNP and ACh during acute over-inflation. *: Signifi-
cant difference (p < 0.05) at the single dose between lean and ZDF rats 
during acute over-distension.
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Page 6 of 8weeks of age while plasma glucose and serum triglycer-
ides remaining at high concentration consistent with pre-
vious observations [21,28,29]. It has been suggested that
Rosi may prevent free fatty acid-induced endothelial dys-
function and exert anti-inflammatory and antioxidative
effects directly in the vasculature [20,30-33]. In this study,
we found that Rosi treatment of short time (3 weeks)
blunts adrenergic vasoconstriction in <10-6 mole/L of PE.
Stepp and Frisbee [24] suggested that it is helpful to nor-
malize blood pressure by blockade of the adrenergic
receptor. Rosi may have beneficial effects in T2DM by
partial attenuation (at low concentration) of adrenergic
over-response in addition to the improvement of
endothelial function. Rosi failed to restore the passive
stress-strain relationship and did not have an effect on
increased vascular stiffness after 3 weeks of treatment.
Glycation and matrix deposit result from high glucose
and the proliferation of vascular smooth muscle cells
which might be elicited by activated α-adrenegic recep-
tor. Rosi did not affect the plasma glucose and the expres-
sions of α-adrenoceptor, MMP9, and elastase in the
present study and hence did not restore the altered
mechanical properties of the vessel wall. In fact, previous
observations showed that Rosi increased body weight and
did not improve systemic blood pressure, plasma glucose,
cholesterol, triglycerides, free fatty acids, etc. [5,20,21].
The improvement of endothelial function from Rosi is
not the benefit of weight loss or the reduction of glucose,
triglycerides, and cholesterol. The mechanistic pathways
of Rosi action requires further study.
The mechanical property of blood vessel is one of the
indicators of vascular remodeling [13-17,34,35] and
reflects the make up of extracellular matrices. Our results
indicate that the blood vessel becomes stiffer if it is sub-
Figure 3 The dose-response relation of circumferential tension 
for the various groups. A: Effect of age (11 weeks and 19 weeks) on 
vasoconstriction. B: Effects of Rosi treatment on vasoconstriction. Lean: 
Zucker lean rats. ZDF: ZDF rats. Rosi: rosiglitazone treatment. 11w: 11 
weeks of age. 19w: 19 weeks of age. #: ANOVA indicates significant dif-
ference (p < 0.05) of the dose-response curve between the ZDF rats at 
different age and lean rats. *: Statistical difference (p < 0.05) at single 
dose between ZDF rats at different age and lean rats.
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Figure 4 The passive pressure-diameter relationship of the femo-
ral artery. The vessel segment was fully relaxed in Ca2+ free PSS at 37°C. 
A: The animals in different ages: lean rats (11 weeks of age and 19 
weeks of age) and ZDF rats (11 weeks of age). There is no significant dif-
ference of pressure-diameter relationship among the three groups. B: 
The animals in different groups: age-matched lean rats (19 weeks of 
age), ZDF rats (19 weeks of ages), and ZDF rats treated with Rosi. There 
is significant shift of diameter in ZDF rats at 19 weeks of age and Rosi 
treated ZDF rats in comparison with age-matched lean rats. Lean: 
Zucker lean rats. ZDF: ZDF rats. Rosi: rosiglitazone treatment. 11w: 11 
weeks of age. 19w: 19 weeks of age. * p < 0.05 indicates the statistical 
significance between groups using ANONA analysis.
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Page 7 of 8jected to hyperglycemia for 6 weeks. The hardening of
blood vessel is recognized as one of the mechanisms of
diabetic hypertension and may result in vascular dysfunc-
tion. The treatment of Rosi for 3 weeks in this study failed
to reverse the hardening of blood vessel wall and the
associated remodeling indicated by the expression of
MMP9 and elastase. Reddy, et al showed that treatment
with ciglitazone (an agonist of PPARγ) for 8 weeks ame-
liorated the decrease in elastin contents [16]. The longer
term effect of Rosi on mechanical property and remodel-
ing requires future work.
In summary, the endothelial dysfunction can be
observed in as early as 19 weeks of age in ZDF rat. The
adrenoceptor is activated and the remodeling of extracel-
lular matrices is implicated in diabetic complication in
early age. This study shows that Rosi treatment restores
the endothelial function and adrenergic vasoconstriction
at low concentration of PE. The mechanical properties
along with the expressions of α-adrenoceptor, MMP9,
and elastase are, however, not reversed by three weeks of
Rosi treatment.
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Figure 5 The Kirchhoff stress- Green strain relationship of the 
femoral artery. A: The animals in different ages: lean rats (11 weeks of 
age and 19 weeks of age) and ZDF rats (11 weeks of age). There is no 
significant difference of stress-strain relationship among the three 
groups. B: The animals in different groups: age-matched lean rats (19 
weeks of age), ZDF rats (19 weeks of age), and ZDF rats treated with Ro-
si. In 19 weeks of age, the stress-strain curve of ZDF rats was significant-
ly shifted to left. The Rosi treatment did not reverse the mechanical 
properties of the arteries. * p < 0.05 indicates the statistical significance 
between groups using ANONA analysis. C: The elastic moduli at the 
pressure near physiological state. Lean: Zucker lean rats. ZDF: ZDF rats. 
Rosi: rosiglitazone treatment. 11w: 11 weeks of age. 19w: 19 weeks of 
age. * p < 0.05 indicates the statistical significance in comparison with 
lean rats using student t-test.
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Figure 6 The vascular expressions of eNOS, α-adrenoceptor (α-
AR), MMP9, and elastase. In all four sections, top panel is the bands 
of proteins and bottom panel is the percent intensity of the ratio of the 
bands to β-actin. A: The expression of eNOS. B: The expressions of α-
adrenoceptor. C: The expressions of MMP9. D: The expression of 
elastase. Lean: Zucker lean rats. ZDF: ZDF rats. 11w: 11 weeks of age. 
19w: 19 weeks of age. 19w + V: 19 weeks of age treated with vehicle. 
19w + R: 19 weeks of age treated with Rosi. * p < 0.05 indicates statis-
tical significance when compared with lean rats using student t-test. # 
p < 0.05 indicates statistical significance in comparison of the two 
groups using student t-test.
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